Unknown

Dataset Information

0

Inhibition of an NAD? salvage pathway provides efficient and selective toxicity to human pluripotent stem cells.


ABSTRACT: The tumorigenic potential of human pluripotent stem cells (hPSCs) is a major limitation to the widespread use of hPSC derivatives in the clinic. Here, we demonstrate that the small molecule STF-31 is effective at eliminating undifferentiated hPSCs across a broad range of cell culture conditions with important advantages over previously described methods that target metabolic processes. Although STF-31 was originally described as an inhibitor of glucose transporter 1, these data support the reclassification of STF-31 as a specific NAD? salvage pathway inhibitor through the inhibition of nicotinamide phosphoribosyltransferase (NAMPT). These findings demonstrate the importance of an NAD? salvage pathway in hPSC biology and describe how inhibition of NAMPT can effectively eliminate hPSCs from culture. These results will advance and accelerate the development of safe, clinically relevant hPSC-derived cell-based therapies.

SUBMITTER: Kropp EM 

PROVIDER: S-EPMC4414215 | biostudies-literature | 2015 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Inhibition of an NAD⁺ salvage pathway provides efficient and selective toxicity to human pluripotent stem cells.

Kropp Erin M EM   Oleson Bryndon J BJ   Broniowska Katarzyna A KA   Bhattacharya Subarna S   Chadwick Alexandra C AC   Diers Anne R AR   Hu Qinghui Q   Sahoo Daisy D   Hogg Neil N   Boheler Kenneth R KR   Corbett John A JA   Gundry Rebekah L RL  

Stem cells translational medicine 20150401 5


The tumorigenic potential of human pluripotent stem cells (hPSCs) is a major limitation to the widespread use of hPSC derivatives in the clinic. Here, we demonstrate that the small molecule STF-31 is effective at eliminating undifferentiated hPSCs across a broad range of cell culture conditions with important advantages over previously described methods that target metabolic processes. Although STF-31 was originally described as an inhibitor of glucose transporter 1, these data support the recla  ...[more]

Similar Datasets

| S-EPMC7252647 | biostudies-literature
| S-EPMC6501775 | biostudies-literature
| S-EPMC4986639 | biostudies-literature
| S-EPMC5388814 | biostudies-literature
| S-EPMC6402325 | biostudies-literature
| S-EPMC3482862 | biostudies-literature
| S-EPMC2740465 | biostudies-literature
| S-EPMC9867855 | biostudies-literature
| S-EPMC10276814 | biostudies-literature
| S-EPMC6196523 | biostudies-literature